The  ||| S:0 E:4 ||| DT
role  ||| S:4 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
apelin  ||| S:12 E:19 ||| NN
in  ||| S:19 E:22 ||| IN
pathogenesis  ||| S:22 E:35 ||| NN
of  ||| S:35 E:38 ||| IN
cardiovascular  ||| S:38 E:53 ||| JJ
diseases  ||| S:53 E:62 ||| NNS
and  ||| S:62 E:66 ||| CC
metabolic  ||| S:66 E:76 ||| JJ
disorders  ||| S:76 E:86 ||| NNS
Apelin  ||| S:86 E:93 ||| NNP
is  ||| S:93 E:96 ||| VBZ
a  ||| S:96 E:98 ||| DT
recently  ||| S:98 E:107 ||| RB
discovered  ||| S:107 E:118 ||| VBN
biologically  ||| S:118 E:131 ||| JJ
active  ||| S:131 E:138 ||| JJ
peptide  ||| S:138 E:146 ||| JJ
present  ||| S:146 E:154 ||| NN
in  ||| S:154 E:157 ||| IN
several  ||| S:157 E:165 ||| JJ
isoforms  ||| S:165 E:174 ||| NN
that  ||| S:174 E:179 ||| WDT
are  ||| S:179 E:183 ||| VBP
agonists  ||| S:183 E:192 ||| VBN
for  ||| S:192 E:196 ||| IN
orphan  ||| S:196 E:203 ||| JJ
receptor  ||| S:203 E:212 ||| NN
APJ ||| S:212 E:215 ||| NNP
.  ||| S:215 E:217 ||| .
Apelin  ||| S:217 E:224 ||| NNP
and  ||| S:224 E:228 ||| CC
APJ  ||| S:228 E:232 ||| NNP
receptor  ||| S:232 E:241 ||| NN
were  ||| S:241 E:246 ||| VBD
found  ||| S:246 E:252 ||| VBN
in  ||| S:252 E:255 ||| IN
the  ||| S:255 E:259 ||| DT
central  ||| S:259 E:267 ||| JJ
nervous  ||| S:267 E:275 ||| JJ
system  ||| S:275 E:282 ||| NN
and  ||| S:282 E:286 ||| CC
in  ||| S:286 E:289 ||| IN
different  ||| S:289 E:299 ||| JJ
peripheral  ||| S:299 E:310 ||| JJ
tissues ||| S:310 E:317 ||| NNS
.  ||| S:317 E:319 ||| .
In  ||| S:319 E:322 ||| IN
the  ||| S:322 E:326 ||| DT
cardiovascular  ||| S:326 E:341 ||| JJ
system  ||| S:341 E:348 ||| NN
the  ||| S:348 E:352 ||| DT
peptide  ||| S:352 E:360 ||| NN
is  ||| S:360 E:363 ||| VBZ
present  ||| S:363 E:371 ||| JJ
both  ||| S:371 E:376 ||| CC
in  ||| S:376 E:379 ||| IN
the  ||| S:379 E:383 ||| DT
heart  ||| S:383 E:389 ||| NN
and  ||| S:389 E:393 ||| CC
in  ||| S:393 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
endothelium  ||| S:400 E:412 ||| NN
and  ||| S:412 E:416 ||| CC
smooth  ||| S:416 E:423 ||| JJ
muscles  ||| S:423 E:431 ||| JJ
cells  ||| S:431 E:437 ||| NNS
of  ||| S:437 E:440 ||| IN
the  ||| S:440 E:444 ||| DT
vascular  ||| S:444 E:453 ||| JJ
wall ||| S:453 E:457 ||| NN
.  ||| S:457 E:459 ||| .
Acting  ||| S:459 E:466 ||| VBG
on  ||| S:466 E:469 ||| IN
cardiomyocytes  ||| S:469 E:484 ||| JJ
apelin  ||| S:484 E:491 ||| NNS
exerts  ||| S:491 E:498 ||| VBP
positive  ||| S:498 E:507 ||| JJ
inotropic  ||| S:507 E:517 ||| JJ
effect ||| S:517 E:523 ||| NN
,  ||| S:523 E:525 ||| ,
in  ||| S:525 E:528 ||| IN
the  ||| S:528 E:532 ||| DT
endothelium  ||| S:532 E:544 ||| NN
it  ||| S:544 E:547 ||| PRP
releases  ||| S:547 E:556 ||| VBZ
nitric  ||| S:556 E:563 ||| JJ
oxide ||| S:563 E:568 ||| NN
,  ||| S:568 E:570 ||| ,
which  ||| S:570 E:576 ||| WDT
mediates  ||| S:576 E:585 ||| VBD
its  ||| S:585 E:589 ||| PRP$
vasodilatory  ||| S:589 E:602 ||| JJ
action ||| S:602 E:608 ||| NN
,  ||| S:608 E:610 ||| ,
while  ||| S:610 E:616 ||| IN
acting  ||| S:616 E:623 ||| VBG
directly  ||| S:623 E:632 ||| RB
on  ||| S:632 E:635 ||| IN
smooth  ||| S:635 E:642 ||| JJ
muscles  ||| S:642 E:650 ||| JJ
cells  ||| S:650 E:656 ||| NNS
it  ||| S:656 E:659 ||| PRP
causes  ||| S:659 E:666 ||| VBZ
vasoconstriction ||| S:666 E:682 ||| VBN
.  ||| S:682 E:684 ||| .
Apelin  ||| S:684 E:691 ||| JJ
interacts  ||| S:691 E:701 ||| NN
with  ||| S:701 E:706 ||| IN
other  ||| S:706 E:712 ||| JJ
compounds  ||| S:712 E:722 ||| NNS
regulating  ||| S:722 E:733 ||| VBG
blood  ||| S:733 E:739 ||| NN
pressure ||| S:739 E:747 ||| NN
;  ||| S:747 E:749 ||| :
for  ||| S:749 E:753 ||| IN
instance  ||| S:753 E:762 ||| NN
with  ||| S:762 E:767 ||| IN
angiotensin  ||| S:767 E:779 ||| JJ
II ||| S:779 E:781 ||| NNP
,  ||| S:781 E:783 ||| ,
vasopressin ||| S:783 E:794 ||| NN
,  ||| S:794 E:796 ||| ,
and  ||| S:796 E:800 ||| CC
with  ||| S:800 E:805 ||| IN
the  ||| S:805 E:809 ||| DT
sympathetic  ||| S:809 E:821 ||| JJ
nervous  ||| S:821 E:829 ||| JJ
system ||| S:829 E:835 ||| NN
.  ||| S:835 E:837 ||| .
Special  ||| S:837 E:845 ||| JJ
attention  ||| S:845 E:855 ||| NN
is  ||| S:855 E:858 ||| VBZ
focused  ||| S:858 E:866 ||| VBN
on  ||| S:866 E:869 ||| IN
the  ||| S:869 E:873 ||| DT
possibility  ||| S:873 E:885 ||| NN
of  ||| S:885 E:888 ||| IN
positive  ||| S:888 E:897 ||| JJ
role  ||| S:897 E:902 ||| NN
of  ||| S:902 E:905 ||| IN
apelin  ||| S:905 E:912 ||| NN
in  ||| S:912 E:915 ||| IN
hypertension ||| S:915 E:927 ||| NN
,  ||| S:927 E:929 ||| ,
initial  ||| S:929 E:937 ||| JJ
stages  ||| S:937 E:944 ||| NNS
of  ||| S:944 E:947 ||| IN
heart  ||| S:947 E:953 ||| NN
failure  ||| S:953 E:961 ||| NN
and  ||| S:961 E:965 ||| CC
ischaemic  ||| S:965 E:975 ||| JJ
heart  ||| S:975 E:981 ||| NN
disease ||| S:981 E:988 ||| NN
.  ||| S:988 E:990 ||| .
Synthesis  ||| S:990 E:1000 ||| NNP
of  ||| S:1000 E:1003 ||| IN
apelin  ||| S:1003 E:1010 ||| NN
in  ||| S:1010 E:1013 ||| IN
adipocytes  ||| S:1013 E:1024 ||| JJ
permits  ||| S:1024 E:1032 ||| NNS
to  ||| S:1032 E:1035 ||| TO
include  ||| S:1035 E:1043 ||| VB
this  ||| S:1043 E:1048 ||| DT
peptide  ||| S:1048 E:1056 ||| NN
among  ||| S:1056 E:1062 ||| IN
adipokines ||| S:1062 E:1072 ||| NN
.  ||| S:1072 E:1074 ||| .
In  ||| S:1074 E:1077 ||| IN
the  ||| S:1077 E:1081 ||| DT
adipose  ||| S:1081 E:1089 ||| JJ
tissue  ||| S:1089 E:1096 ||| NN
its  ||| S:1096 E:1100 ||| PRP$
production  ||| S:1100 E:1111 ||| NN
is  ||| S:1111 E:1114 ||| VBZ
increased  ||| S:1114 E:1124 ||| VBN
in  ||| S:1124 E:1127 ||| IN
obesity  ||| S:1127 E:1135 ||| NN
and  ||| S:1135 E:1139 ||| CC
by  ||| S:1139 E:1142 ||| IN
insulin ||| S:1142 E:1149 ||| NN
.  ||| S:1149 E:1151 ||| .
It  ||| S:1151 E:1154 ||| PRP
appears  ||| S:1154 E:1162 ||| VBZ
that  ||| S:1162 E:1167 ||| DT
apelin  ||| S:1167 E:1174 ||| NN
may  ||| S:1174 E:1178 ||| MD
play  ||| S:1178 E:1183 ||| VB
essential  ||| S:1183 E:1193 ||| JJ
role  ||| S:1193 E:1198 ||| NN
in  ||| S:1198 E:1201 ||| IN
pathogenesis  ||| S:1201 E:1214 ||| NN
of  ||| S:1214 E:1217 ||| IN
insulin-resistant  ||| S:1217 E:1235 ||| JJ
obesity ||| S:1235 E:1242 ||| NN
.  ||| S:1242 E:1244 ||| .
In  ||| S:1244 E:1247 ||| IN
patients  ||| S:1247 E:1256 ||| NNS
with  ||| S:1256 E:1261 ||| IN
type  ||| S:1261 E:1266 ||| NN
2  ||| S:1266 E:1268 ||| CD
diabetes  ||| S:1268 E:1277 ||| NN
apelin  ||| S:1277 E:1284 ||| NN
improves  ||| S:1284 E:1293 ||| VBZ
glucose  ||| S:1293 E:1301 ||| JJ
tolerance  ||| S:1301 E:1311 ||| NN
in  ||| S:1311 E:1314 ||| IN
initial  ||| S:1314 E:1322 ||| JJ
stages  ||| S:1322 E:1329 ||| NNS
of  ||| S:1329 E:1332 ||| IN
the  ||| S:1332 E:1336 ||| DT
illness ||| S:1336 E:1343 ||| NN
.  ||| S:1343 E:1345 ||| .
However ||| S:1345 E:1352 ||| RB
,  ||| S:1352 E:1354 ||| ,
further  ||| S:1354 E:1362 ||| RB
experimental  ||| S:1362 E:1375 ||| JJ
and  ||| S:1375 E:1379 ||| CC
clinical  ||| S:1379 E:1388 ||| JJ
studies  ||| S:1388 E:1396 ||| NNS
are  ||| S:1396 E:1400 ||| VBP
required  ||| S:1400 E:1409 ||| VBN
for  ||| S:1409 E:1413 ||| IN
full  ||| S:1413 E:1418 ||| JJ
evaluation  ||| S:1418 E:1429 ||| NN
of  ||| S:1429 E:1432 ||| IN
significance  ||| S:1432 E:1445 ||| NN
of  ||| S:1445 E:1448 ||| IN
positive  ||| S:1448 E:1457 ||| JJ
and  ||| S:1457 E:1461 ||| CC
negative  ||| S:1461 E:1470 ||| JJ
aspects  ||| S:1470 E:1478 ||| NNS
of  ||| S:1478 E:1481 ||| IN
the  ||| S:1481 E:1485 ||| DT
role  ||| S:1485 E:1490 ||| NN
of  ||| S:1490 E:1493 ||| IN
apelin  ||| S:1493 E:1500 ||| NN
in  ||| S:1500 E:1503 ||| IN
the  ||| S:1503 E:1507 ||| DT
cardiovascular  ||| S:1507 E:1522 ||| JJ
and  ||| S:1522 E:1526 ||| CC
metabolic  ||| S:1526 E:1536 ||| JJ
diseases ||| S:1536 E:1544 ||| NNS
.  ||| S:1544 E:1546 ||| .
